← Back to Screener
BeyondSpring Inc. Ordinary Shares (BYSI)
Price$1.73
Favorite Metrics
Price vs S&P 500 (26W)-9.32%
Price vs S&P 500 (4W)-1.37%
Market Capitalization$71.14M
All Metrics
Book Value / Share (Quarterly)$0.21
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.48
Price vs S&P 500 (YTD)2.00%
Net Profit Margin (TTM)-4750.48%
EPS (TTM)$-0.02
10-Day Avg Trading Volume0.01M
EPS Excl Extra (TTM)$-0.02
EPS (Annual)$-0.02
ROI (Annual)-227.16%
Net Profit Margin (5Y Avg)-9233.73%
Cash / Share (Quarterly)$0.31
ROA (Last FY)-3.88%
EBITD / Share (TTM)$-0.22
ROE (5Y Avg)-174.61%
Operating Margin (TTM)-4903.03%
Cash Flow / Share (Annual)$-0.48
P/B Ratio8.77x
P/B Ratio (Quarterly)6.92x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)46.89x
Net Interest Coverage (TTM)-236.00x
ROA (TTM)-3.26%
EPS Incl Extra (Annual)$-0.02
Current Ratio (Annual)1.54x
Quick Ratio (Quarterly)1.52x
3-Month Avg Trading Volume0.18M
52-Week Price Return37.30%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$-0.15
P/S Ratio (Annual)52.66x
Asset Turnover (Annual)0.03x
52-Week High$3.44
Operating Margin (5Y Avg)-9191.78%
EPS Excl Extra (Annual)$-0.02
CapEx CAGR (5Y)-0.78%
26-Week Price Return-0.57%
Quick Ratio (Annual)1.52x
13-Week Price Return3.59%
Total Debt / Equity (Annual)0.06x
Current Ratio (Quarterly)1.54x
Enterprise Value$63.351
Asset Turnover (TTM)0.01x
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-2673.35%
Cash / Share (Annual)$0.31
3-Month Return Std Dev58.04%
Net Income / Employee (TTM)$-0
ROE (Last FY)-240.51%
Net Interest Coverage (Annual)-29.23x
EPS Basic Excl Extra (Annual)$-0.02
Receivables Turnover (TTM)0.00x
Total Debt / Equity (Quarterly)0.06x
EPS Incl Extra (TTM)$-0.02
ROI (TTM)-128.17%
P/S Ratio (TTM)52.66x
Pretax Margin (5Y Avg)-9104.20%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$-0.15
Forward P/E0.81x
Price vs S&P 500 (52W)2.21%
Year-to-Date Return6.13%
5-Day Price Return-1.15%
EPS Normalized (Annual)$-0.02
ROA (5Y Avg)-54.33%
Net Profit Margin (Annual)-2463.29%
Month-to-Date Return5.49%
EBITD / Share (Annual)$-0.22
Operating Margin (Annual)-2756.40%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-170.11%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-0.02
P/B Ratio (Annual)6.64x
Pretax Margin (TTM)-4784.46%
Book Value / Share (Annual)$0.69
Price vs S&P 500 (13W)0.73%
Beta0.45x
Revenue / Share (TTM)$0.00
ROE (TTM)-133.13%
52-Week Low$1.21
Analyst Recommendations
Mar 2024
Apr 2024
May 2024
Jun 2024
4.29
4.29
4.29
4.29
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
BYSIBeyondSpring Inc. Ordinary Shares | 52.66x | — | — | — | $1.73 |
LLYEli Lilly & Co. | 13.44x | 44.70% | 83.04% | 27.59% | $927.03 |
JNJJohnson & Johnson | 5.85x | 7.87% | 67.95% | 14.90% | $234.18 |
ABBVABBVIE INC. | 6.03x | 8.57% | 71.62% | -2.88% | $208.38 |
MRKMerck & Co., Inc. | 4.53x | 1.31% | 78.55% | 21.23% | $119.07 |
AZNAstraZeneca PLC | 5.30x | 8.63% | 81.31% | 21.88% | $204.80 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $151.97 |
NVONovo-Nordisk A/S | 3.70x | 6.43% | 80.98% | 20.66% | $40.52 |
ABTAbbott Laboratories | 3.74x | 6.59% | 56.50% | 8.20% | $96.81 |
PFEPfizer Inc. | 2.51x | -1.64% | 75.81% | -3.51% | $27.56 |
BMYBristol-Myers Squibb Co. | 2.55x | -0.22% | 72.63% | — | $60.17 |
About
BeyondSpring Inc is a clinical-stage biopharmaceutical company developing cancer therapies with a focus on immuno-oncology. The company's lead program, Plinabulin, is an investigational agent in clinical development for oncology indications.